Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 129.49 |
| Open | 128.84 |
| Bid | 0.00 x 800 |
| Ask | 126.07 x 1800 |
| Day's Range | 125.74 - 129.08 |
| 52 Week Range | 99.14 - 133.10 |
| Volume | |
| Avg. Volume | 8,294,460 |
| Market Cap | 319.362B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 143.28 |
| EPS (TTM) | 0.88 |
| Earnings Date | Jul 30, 2024 |
| Forward Dividend & Yield | 3.08 (2.38%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | 142.18 |
Business WireMerck to Acquire EyeBio
RAHWAY, N.J. & NEW YORK, May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
ReutersMerck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.
- Investing.com
Merck nears $1.3 bln takeover of Eyebiotech- WSJ
Investing.com-- Merck&Company Inc (NYSE:MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall Street Journal reported on Tuesday.
© 2024 Yahoo. All rights reserved.